Posts Tagged ‘Treatment’
Treatment of Polymyalgia Rheumatica: A Systematic Review [Review Article]
October 1st, 2011 | 
Author: Conclusions The scarcity of randomized trials and the high level of heterogeneity of studies on PMR therapy do not allow firm conclusions to be drawn. However, PMR remission seems to be achieved with prednisone treatment at a dose of 15 mg/d in most patients, and reductions below 10 mg/d should preferably follow a tapering rate of less than 1 mg/mo. Methotrexate seems to exert glucocorticoid-sparing properties. (Source: Archives of Internal Medicine)
MedWorm: Polymyalgia Rheumatica
Systematic review: Treatment of polymyalgia rheumatica
Source: Arch Internal Med
Area: News
A systematic review of the evidence on treatment of polymyalgia rheumatica concludes that there is a scarcity of controlled trials and significant heterogeneity in those that exist; as a result, it is not possible to draw firm conclusions on the optimum treatment.
Polymyalgia rheumatica (PMR) is a syndrome that occurs in people aged over 50 and presents with morning stiffness and aching in the shoulder and pelvic girdles, with signs of systemic inflammation. Systemic corticosteroids are the standard treatment, however there have been no systematic summaries of the evidence for corticosteroid or other therapy: the authors of this review aimed to determine whether there was evidence to indicate the optimum corticosteroid, dose, and dose reduct…
Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica
This study is concerned with an evaluation of the effects of glucocorticoids (GC) on adiponectin and leptin concentrations in patients with polymyalgia rheumatica (PMR). Seven patients diagnosed with PMR were studied at baseline and after one and three months of prednisone treatment. Serum leptin and adiponectin, serum glucose and insulin, erythrocyte sedimentation rate, C-reactive protein, and IL-6 were all measured by commercial assays. The treatment with GC normalized inflammation markers and significantly increased adiponectin and leptin concentrations without any impairment of insulin sensitivity measured by HOMA-IR. Adiponectin significantly increased only between baseline and 1 month (P= 0.013). A significant correlation was found between adiponectin and leptin concentrations both a…
MedWorm: Polymyalgia Rheumatica
Latest Polymyalgia Rheumatica Symptoms And Treatment News
Zalicus Initiates Phase 2b Clinical Trial of Synavive in Rheumatoid Arthritis
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zalicus initiates Phase 2b clinical study of Synavive in RA patients
Read more on Business Wire
Polymyalgia Rheumatica: Steroids and Beyond: Lower doses of prednisone and a greater use of biologics are on the PMR treatment horizon.
ROME â A newly launched clinical trial is examining whether adrenal insufficiency contributes to the pathology of polymyalgia rheumatica. If the study yields data to support the adrenal insufficiency hypothesis, it’s quite possible that doses lower than the currently recommended 15-20 mg/day would achieve equal disease control with fewer steroid side effects, according to Dr. Marco A. Cimmino, one of the investigators. (Source: Rheumatology News)
FDA Approves YERVOY™ (Ipilimumab) For The Treatment Of Patients With Newly Diagnosed Or Previously-Treated …
FDA Approves YERVOY™ (Ipilimumab) For The Treatment Of Patients With Newly Diagnosed Or Previously-Treated …
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved YERVOY™ (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma. YERVOY is the first and only therapy for unresectable or metastatic melanoma to demonstrate a significant improvement in overall survival based on results from a pivotal …
Read more on Medical News Today